Frequency and distribution of late gadolinium enhancement in magnetic resonance imaging of patients with apical hypertrophic cardiomyopathy and patients with asymmetrical hypertrophic cardiomyopathy: A comparative study

International Journal of Cardiovascular Imaging

Volumn 25, Issue SUPPL. 1, 2009, Pages 131-138

  Yamada, Masao ^a   Teraoka, Kunihiko ^a   Kawade, Masafumi ^a   Hirano, Masaharu ^a   Yamashina, Akira ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Apical hypertrophic cardiomyopathy; Cardiomyopathy; Late gadolinium enhancement; Magnetic resonance imaging

Indexed keywords

GADOLINIUM PENTETATE;

ADULT; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE PROCESSING; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOLOGICAL PARAMETERS;

ADULT; AGED; AGED, 80 AND OVER; CARDIOMYOPATHY, HYPERTROPHIC; CONTRAST MEDIA; DISEASE PROGRESSION; ELECTROCARDIOGRAPHY; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 64249110165     PISSN: 15695794     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10554-008-9406-1     Document Type: Article

References (19)

1. Richardson P, McKenna W, Bristow M et al (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation 93(5):841-842
2. Maron BJ, Wolfson JK, Ciró E et al (1983) Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. Am J Cardiol 51(1):189-194. doi: 10.1016/S0002-9149(83)80034-4
3. Sakamoto T (2001) Apical hypertrophic cardiomyopathy (apical hypertrophy): An overview. J Cardiol 37(Suppl. 1):161-178
4. Eriksson MJ, Sonnenberg B, Woo A et al (2002) Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 39(4):638-645. doi: 10.1016/S0735-1097(01)01778-8
5. Zenovich AG, Lesser JR, Casey SA et al (2004) Images in cardiovascular medicine. Hypertrophic cardiomyopathy with apical aneurysm. Circulation 110(16):e450. doi: 10.1161/01.CIR.0000145174.74063.C1
6. Sato A, Shiga T, Kawarai H et al (2003) Apical hypertrophic cardiomyopathy with aneurysmal degeneration of the apex. Heart Vessels 18(1):53-54. doi: 10.1007/s003800300010
7. Suzuki J, Shimamoto R, Nishikawa J et al (1999) Morphological onset and early diagnosis in apical hypertrophic cardiomyopathy: A long term analysis with nuclear magnetic resonance imaging. J Am Coll Cardiol 33(1):146-151. doi: 10.1016/S0735-1097(98)00527-0
8. Moon JC, Fisher NG, McKenna WJ et al (2004) Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 90(6):645-649. doi: 10.1136/hrt.2003.014969
9. Budoff MJ, Cohen MC, Garcia MJ et al (2005) ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance: A report of the American College of Cardiology Foundation/ American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. J Am Coll Cardiol 46(2):383-402. doi: 10.1016/j.jacc.2005.04.033
10. Kim RJ, Fieno DS, Parrish TB et al (1999) Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100(19):1992-2002
11. Kim RJ, Wu E, Rafael A et al (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343(20):1445-1453. doi: 10.1056/ NEJM200011163432003
12. Choudhury L, Mahrholdt H, Wagner A et al (2002) Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40(12):2156-2164. doi: 10.1016/ S0735-1097(02)02602-5
13. Moon JC, McKenna WJ, McCrohon JA et al (2003) Toward clinical risk assessment in hypertrophy cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41(9):1561-1567. doi: 10.1016/ S0735-1097(03)00189-X
14. Teraoka K, Hirano M, Ookubo H et al (2004) Delayed contrast enhancement of MRI in hypertrophy cardiomyopathy. Magn Reson Imaging 22(2):155-161. doi: 10.1016/j.mri.2003.08.009
15. Maron BJ, Tholakanahalli VN, Zenovich AG et al (2004) Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 109(8):984-989. doi: 10.1161/ 01.CIR.0000117098.75727.D8
16. Cerqueira MD, Weissman NJ, Dilsizian V et al (2002) Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105(4):539-542. doi: 10.1161/hc0402.102975
17. Wigle ED (2001) Cardiomyopathy: The diagnosis of hypertrophic cardiomyopathy. Heart 86(6):709-714. doi: 10.1136/heart.86.6.709
18. Moon JC, Reed E, Sheppard MN et al (2004) The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43(12):2260-2264. doi: 10.1016/ j.jacc.2004.03.035
19. Gebker R, Neuss M, Paetsch I et al (2006) Images in cardiovascular medicine. Progressive myocardial fibrosis in a patient with apical hypertrophic cardiomyopathy detected by cardiovascular magnetic resonance. Circulation 114(5):e75-e76. doi: 10.1161/ CIRCULATIONAHA.106.612994